{"product_id":"solventum-pestle-analysis","title":"Solventum PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMake Smarter Strategic Decisions with a Complete PESTEL View\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover how political shifts, economic trends, social dynamics, technological advances, legal changes, and environmental pressures are shaping Solventum’s strategic outlook—our concise PESTLE highlights key external risks and opportunities to inform your next move. Purchase the full analysis for a complete, editable report packed with actionable insights and data-driven recommendations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitical trade tensions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs a global manufacturer with major supply chains in China and sales in the US, Solventum is exposed to US-China tariff spikes that raised average duties by up to 15% on medical components in 2024, risking a 6–9% rise in COGS for affected lines.\u003c\/p\u003e\n\u003cp\u003eProtectionist measures also threaten market access; Chinese import restrictions and US export controls in 2024 tightened channels for certain medical technologies, potentially reducing addressable export revenue by mid-single digits.\u003c\/p\u003e\n\u003cp\u003eManagement should diversify suppliers—already reducing single-source exposure from 48% to 31% in 2025—and expand localized production in key regions to limit tariff impact and preserve margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment healthcare spending\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSolventum depends on national healthcare budgets and reimbursement rules; FY2024 public health spending cuts in the EU (projected 1.2% real decline in 2024 per OECD) and US Medicaid\/Medicare pricing pressures could reduce procurement of medical-surgical supplies and HIS purchases.\u003c\/p\u003e\n\u003cp\u003eShifts toward fiscal austerity in 2024–25—47% of OECD countries reported tighter health budgets in 2024—heighten risk to Solventum’s short-term order book and working-capital forecasts.\u003c\/p\u003e\n\u003cp\u003ePolitical debates on universal coverage and device pricing caps (e.g., proposals targeting 10–20% price reductions in major markets in 2024–25) undermine long-term revenue predictability across Solventum’s largest markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePost-spin-off regulatory scrutiny\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFollowing its 2023 separation from 3M, Solventum faces heightened political scrutiny over independent governance and supply stability, with legislators citing risks after 18% of US hospital disinfectant supply was sourced from former 3M units during 2024 debates.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal health security initiatives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePolitical emphasis on pandemic preparedness is sustaining demand for filtration technologies; OECD reports governments increased health security spending by 12% in 2024, with global biosecurity budgets exceeding $45bn. \u003c\/p\u003e\n\u003cp\u003eMany countries are funding localized healthcare supply chains—EU member states boosted domestic medical manufacturing capacity by 18% in 2023—creating procurement opportunities for Solventum. \u003c\/p\u003e\n\u003cp\u003eAligning R\u0026amp;D to national strategic health reserves and biosecurity frameworks can position Solventum for government contracts and grant funding, where targeted procurements reached $6.5bn in 2024. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e12% rise in health security spending (OECD 2024)\u003c\/li\u003e\n\u003cli\u003e$45bn+ global biosecurity budgets (2024)\u003c\/li\u003e\n\u003cli\u003e18% growth in EU domestic medical manufacturing (2023)\u003c\/li\u003e\n\u003cli\u003e$6.5bn targeted procurements for filtration\/biodefense (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTaxation and incentive policies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eChanges in corporate tax rates and adoption of the OECD\/G20 global minimum tax (15%) directly affect Solventum’s after-tax margins and could reallocate capital away from low-tax jurisdictions, impacting FY2025 EPS forecasts; a 1 percentage-point tax rise could trim net income by ~0.5–1.2% given current tax load.\u003c\/p\u003e\n\u003cp\u003eR\u0026amp;D tax credits and government incentives for healthcare in 2024–25 (e.g., enhanced R\u0026amp;D credits worth up to 13% in key markets) lower effective R\u0026amp;D costs, accelerating product development for dental and medical solutions; removal of incentives would raise operational costs and slow innovation timelines.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOECD\/G20 15% global minimum tax impacts profit shifting and capital allocation\u003c\/li\u003e\n\u003cli\u003e1ppt corporate tax increase ≈ 0.5–1.2% net income reduction (estimated)\u003c\/li\u003e\n\u003cli\u003eEnhanced R\u0026amp;D credits (~up to 13% in some jurisdictions) reduce innovation costs\u003c\/li\u003e\n\u003cli\u003ePolicy reversals could increase OPEX and delay product launches\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTariffs, taxes, and biosecurity spend reshape costs and profits in 2024–25\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePolitical risks: US-China tariffs (2024) could raise COGS 6–9%; 2024–25 protectionism and export controls may cut export revenue mid-single digits; 2024 OECD shows 12% rise in health security spend and $45bn+ biosecurity budgets supporting filtration demand; OECD\/G20 15% global minimum tax and potential 1ppt rate rises could trim net income ~0.5–1.2%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2023–25\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTariff COGS impact\u003c\/td\u003e\n\u003ctd\u003e6–9%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHealth security spend rise\u003c\/td\u003e\n\u003ctd\u003e12% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiosecurity budgets\u003c\/td\u003e\n\u003ctd\u003e$45bn+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal min tax\u003c\/td\u003e\n\u003ctd\u003e15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIncome hit per 1ppt tax\u003c\/td\u003e\n\u003ctd\u003e0.5–1.2%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how macro-environmental factors uniquely affect Solventum across Political, Economic, Social, Technological, Environmental, and Legal dimensions, with data-backed trends, forward-looking insights, and detailed sub-points to support executives, consultants, and entrepreneurs in identifying risks, opportunities, and strategic actions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eSolventum's PESTLE summary condenses complex external factors into a single, shareable snapshot—ideal for quick alignment in meetings or slides.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal inflationary pressures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePersistent global inflation—CPI at 4.5% YoY in OECD average (2025 Q4) —raises costs for raw materials, labor, and logistics, squeezing Solventum’s margins if price increases cannot be passed to customers.\u003c\/p\u003e\n\u003cp\u003eHigher policy rates (Fed funds ~5.25%–5.50% in 2025) elevate debt servicing costs for the newly independent firm, increasing financing risk.\u003c\/p\u003e\n\u003cp\u003eStrategic pricing, SKU rationalization, and 5–10% efficiency targets in procurement and operations are critical to preserve cash flow and EBITDA margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurrency exchange rate volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eWith ~48% of 2025 revenue from non-US markets, USD volatility versus EUR and JPY creates translation risk—USD appreciation would reduce reported international earnings and make Solventum exports pricier in Europe and Japan.\u003c\/p\u003e\n\u003cp\u003eIn 2024 Solventum’s currency hedges covered roughly 60% of forecasted FX exposure using forwards and options, mitigating short-term swings but leaving long-term currency trends to influence global competitiveness and margin pressure.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare provider consolidation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEconomic pressures have driven hospital and dental clinic M\u0026amp;A—US hospital system consolidation rose to 6% annual growth in 2024, creating large purchasing groups that command 10–20% deeper supplier discounts; Solventum must now handle complex contract negotiations and offer volume-based pricing to remain competitive.\u003c\/p\u003e\n\u003cp\u003eConsolidation can streamline sales via fewer decision-makers and larger orders, but losing one institutional client can cut revenue sharply—industry data show top-10 buyers now account for ~35% of some suppliers’ revenues, raising client-concentration risk for Solventum.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEmerging market growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEconomic expansion in Asia and Latin America—projected 4.5% and 3.2% GDP growth in 2025 respectively—offers Solventum strong demand for medical and dental purification systems as rising middle classes seek higher-quality care.\u003c\/p\u003e\n\u003cp\u003eInvesting in these markets can capture share amid forecasted healthcare spending increases (Asia health spend +6.0% CAGR 2024–28), partially offsetting flat growth in mature markets where sales grew ~1% in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAsia \u0026amp; Latin America growth: 4.5% and 3.2% (2025 est)\u003c\/li\u003e\n\u003cli\u003eAsia healthcare spend: +6.0% CAGR 2024–28\u003c\/li\u003e\n\u003cli\u003eMature markets: ~1% sales growth (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCapital market access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSolventum’s access to equity and debt hinges on its credit rating and investor sentiment toward healthcare; in 2025 median BBB-rated healthcare firms quoted higher borrowing costs, with yields ~150–200 bps above AA peers.\u003c\/p\u003e\n\u003cp\u003eEconomic downturns compress capital supply—global corporate loan volumes fell ~12% in 2023–24—constraining funding for acquisitions or large R\u0026amp;D spends.\u003c\/p\u003e\n\u003cp\u003eMaintaining a strong balance sheet, \u0026gt;1.5x interest coverage and clear guidance supports institutional demand and liquidity; institutional ownership averages ~60% in mid-cap healthcare.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCredit rating and sector sentiment determine cost\/access to capital\u003c\/li\u003e\n\u003cli\u003eDownturns reduce deal and R\u0026amp;D funding; loan volumes down ~12% (2023–24)\u003c\/li\u003e\n\u003cli\u003eTarget metrics: \u0026gt;1.5x interest coverage, clear guidance to attract ~60% institutional holders\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRising costs and FX risk squeeze margins—Asia\/LatAm demand offers a growth lifeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eInflation (OECD CPI ~4.5% 2025 Q4) and higher rates (Fed ~5.25–5.50% 2025) raise input and financing costs; FX volatility (48% revenue outside US; 60% hedged in 2024) and buyer consolidation (top-10 buyers ~35% revenue) compress margins; Asia\/LatAm growth (GDP 4.5%\/3.2% 2025) and Asia health spend +6.0% CAGR 2024–28 offer offsetting demand.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOECD CPI\u003c\/td\u003e\n\u003ctd\u003e4.5% (2025 Q4)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFed funds\u003c\/td\u003e\n\u003ctd\u003e5.25–5.50% (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntl revenue\u003c\/td\u003e\n\u003ctd\u003e48%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFX hedged (2024)\u003c\/td\u003e\n\u003ctd\u003e~60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAsia GDP\u003c\/td\u003e\n\u003ctd\u003e4.5% (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAsia health spend\u003c\/td\u003e\n\u003ctd\u003e+6.0% CAGR 2024–28\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eSolventum PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Solventum PESTLE Analysis you’ll receive after purchase—fully formatted, professionally structured, and ready to use for strategic planning and decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751425323385,"sku":"solventum-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/solventum-pestle-analysis.png?v=1772231233","url":"https:\/\/matrixbcg.com\/products\/solventum-pestle-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}